Background: The issue of subpar and counterfeit medications is one that many nations face. This leads to potentially fatal situations, financial losses for consumers, and a decline in public confidence in the healthcare system. The evaluation of medicine quality available in the Nepalese market is the focus of this study. Techniques: A cross-sectional survey was conducted in the valley of Kathmandu. Purposively, five distinct brand names were chosen from each of the eight drug molecules (Paracetamol tablet, Cloxacillin capsule, Amlodipine tablet, Metformin tablet, Losartan tablet, Cefixime tablet, Ofloxacin tablet, Carbamazepine tablet). The Department of Drug Administration (DDA) confirmed registration compliance, and two distinct laboratories conducted laboratorial analyses. Findings: Of 40 medicine samples, 90% did not meet the current labeling regulations, and 42.5% of brands omitted any reference to the pharmacopoeial norm. The selflife was mentioned inconsistently. Large variations in the prices of identical generic medications were also observed. According to laboratory examination, 28% of samples from foreign brands and 40% from domestic companies did not fulfill the requirement. It was shown that 32.5% of the samples were of inferior quality overall. One sample's result was the only one that agreed with both labs. This suggests that there were differences between the two laboratories that were chosen. Conclusions: According to the survey's results, Nepalese consumers can purchase inferior medications. Furthermore, comparable pharmaceutical items lack standardization and are subject to lax regulation. To assess the quality of pharmaceutical items available in the Nepalese market, a more extensive investigation involving product testing in more than two independent laboratories is needed.

fake medications, inferior medications, and medication quality.